Rosanne Michie of Optometry Austrialia reviews Okogen’s upcoming Australian trial that aims to fill the absence of approved therapies to treat the underlying cause of viral conjunctivitis.
Menu
Rosanne Michie of Optometry Austrialia reviews Okogen’s upcoming Australian trial that aims to fill the absence of approved therapies to treat the underlying cause of viral conjunctivitis.
© 2021 Okogen, Inc. All Rights Reserved
United States
Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA
Australia
Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS
